FDA Grants Priority Review to Takeda's Oveporexton, the First Orexin Agonist to Reach the Doorstep of Approval for Narcolepsy Type 1
Takeda's oveporexton, an oral drug that restores the brain chemical missing in narcolepsy type 1, has received FDA priority review after two Phase 3 trials showed it brought patients to near-normal wakefulness and cut cataplexy episodes by more than 80 percent.
4 min read3 sources